Compare W W Grainger Inc (GWW) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
W W Grainger Inc vs IDEXX Laboratories, Inc. — how do they compare? W W Grainger Inc trades at $1,289.35 (market cap $59.76B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: W W Grainger Inc is the larger of the two by market cap, and W W Grainger Inc pays a 0.79% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold W W Grainger Inc for 25 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| GWW | IDXX | |
|---|---|---|
Market Cap | $59.76B | $40.43B |
Volume | 186,697 | 692,164 |
Sector | Industrials | Health |
52-Week High | $1.40K | $766.68 |
52-Week Low | $918.18 | $504.70 |
Typical Hold Time | 25 Days | 46 Days |
Enterprise Value | $61.96B | $41.32B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
W.W. Grainger (GWW) trades at $1,263.51, down 0.94% on the day, amid a bearish technical signal. Recent earnings show mixed results with Q4 2025 missing estimates but Q1 and Q2 2026 beating expectations. The company maintains strong profitability with a net income margin of 9.92% and ROE of 47.92%, though valuation ratios like P/E of 32.34 appear elevated. Recent news highlights institutional buying and expansion efforts, including a new distribution center in Oregon and the acquisition of technology assets from Adroit Worldwide Media.
The outlook for GWW is cautiously optimistic, supported by earnings beats and solid fundamentals, but risks include high valuation and competitive pressures. Analyst consensus leans hold with a $1,310 price target, suggesting limited upside. Investors should weigh strong cash flow and dividend consistency against potential margin compression and market volatility.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
